Table 1.

Discharge Medications Among 31,994 Patients in the LAAO Registry Between January 2016 and November 2018.

Discharge Medications (Not Mutually Exclusive)	Number	(%)
Aspirin	21,714	(67.87)
Warfarin	17,774	(55.55)
DOAC*	11,658	(36.44)
P2Y12 inhibitor†	4,229	(13.22)
Bridging anticoagulant therapy‡	335	(1.05)
None of anticoagulation or antiplatelet therapy or P2Y12 or bridging	583	(1.82)
Most Common Discharge Medication Strategies (Mutually-Exclusive Groupings)
Warfarin and aspirin	11,811	(36.92)
Warfarin only	4,330	(13.53)
DOAC and aspirin	6,649	(20.78)
DOAC only	3,948	(12.34)
DAPT (aspirin and P2Y12 inhibitor)	1,614	(5.04)
Other	3,642	(11.38)

^*Includes apixaban, dabigatran, rivaroxaban or edoxaban

^†P2Y12 inhibitor includes clopidogrel, prasugrel, ticlopidine, ticagrelor

^‡Bridging anticoagulation therapy includes unfractionated heparin, fondaparinux, low molecular weight heparin, heparin derivatives

DAPT = dual antiplatelet therapy; DOAC = direct oral anticoagulant; LAOO = left atrial appendage occlusion